Recurrent Ischemia & Nitroglycerin Dosing

Hello, During a recent transport lasting over two hours, a patient’s suspected ischemic chest pain resolved following nitroglycerin, then recurred. I restarted nitroglycerin as all the directive conditions were still within the necessary clinical parameters. I could not find specific guidance on recurrent episodes in the current Cardiac Ischemia Medical Directive. Could you clarify whether each recurrence after complete symptom relief can be treated as a new episode and also that the applicable nitroglycerin dose maximum of 6 also remains the same. My previous experience and understanding was that a new episode could be treated with a new dosing sequence. Look forward to your help. P.S. Related: If a patient with STEMI were to achieve symptom relief with the maximum 3 doses of nitroglycerin, but symptoms subsequently recur, can nitroglycerin likewise be restarted with a fresh 3-dose maximum, or is the 3 maximum an absolute limit in STEMI circumstances?

Thank you for reaching out regarding recurrent chest pain and the application of the Cardiac Ischemia Medical Directive. Under the Advanced Life Support Patient Care Standards (ALS PCS), Version 5.4, complete symptom relief followed by recurrence does not reset the nitroglycerin dosing sequence or the applicable maximum number of doses. Previously administered doses remain part of the same treatment sequence, regardless of symptom recurrence or transport duration. The maximum number of nitroglycerin doses remains:• Without identified STEMI: A maximum of six doses.• With identified STEMI: A maximum of three doses. Symptom resolution followed by recurrence should not be interpreted as a new episode that permits restarting the dosing sequence. It is important to recognize that while nitroglycerin may provide symptomatic relief, it does not resolve the underlying coronary occlusion. Temporary symptom relief does not exclude ongoing myocardial ischemia or infarction. Recurrent chest pain should prompt a thorough reassessment of the patient's clinical status, including vital signs and a repeat 12-lead ECG to identify potential evolving ischemic changes. Paramedics should remain mindful of the potential adverse effects of nitroglycerin, particularly hypotension, which may compromise coronary perfusion and worsen myocardial ischemia. Timely transport and appropriate notification of the receiving facility should remain priorities. Online Medical Consultation (OMC) should be considered when additional clinical guidance is required. In summary, recurrent chest pain does not independently authorize a new nitroglycerin dosing sequence. Paramedics must continue to adhere to the maximum dosing limits outlined in ALS PCS Version 5.4 while reassessing the patient for evolving clinical or ECG findings.